Table 1.
Clinical characteristics of patients enrolled at the time of MDT.
| Overall | [18F]F-Fluorocholine Guided MDT | [68Ga]Ga-PSMA-11 Guided MDT | p Value | |
|---|---|---|---|---|
| Number of patients | 37 | 11 | 26 | |
| ISUP grade | ||||
| ISUP 1 | 8 (21.6%) | 2 (18.2%) | 6 (23.1%) | 0.747 |
| ISUP 2 | 8 (21.6%) | 3 (27.3%) | 5 (19.2%) | |
| ISUP 3 | 8 (21.6%) | 1 (9.0%) | 7 (27.0%) | |
| ISUP 4 | 8 (21.6%) | 3 (27.3%) | 5 (19.2%) | |
| ISUP 5 | 5 (13.6%) | 2 (18.2%) | 3 (11.5%) | |
| Primary treatment (radiotherapy vs. surgery) | ||||
| Surgery | 29 (78.4%) | 7 (63.6%) | 22 (84.6%) | 0.157 |
| Radiotherapy (± ADT) | 8 (21.6%) | 4 (36.4%) | 4 (15.4%) | |
| Previous salvage radiotherapy | 29 (78.4%) | 9 (81.8%) | 20 (76.9%) | 0.741 |
| Time to oligometastases, months (range) | 91 (2–245) | 79 (2–209) | 104 (2–245) | 0.551 |
| Age at MDT | 73.7 ± 7.57 | 70.45 ± 8.9 | 75.08 ± 6.65 | 0.142 |
| CRPC at MDT | 8 (21.6%) | 3 (27.3%) | 5 (19.2%) | 0.587 |
| PSA pre-MDT | 3.01 ± 6.34 | 4.19 ± 5.38 | 2.5 ± 6.74 | 0.468 |
| Medical therapy in addition to MDT | 29 (78.4%) | 10 (90.9%) | 19 (73.2%) | 0.228 |
| PSA nadir after MDT | 0.76 ± 0.1 | 1.54 ± 1.83 | 0.43 ± 0.91 | 0.018 |
| Time to PSA nadir, months (range) | 4 (1–29) | 4 (1–17) | 5 (1–29) | 0.545 |
| Number of metastases treated with MDT | ||||
| 1 lesion | 30 (81.0%) | 11 (100%) | 19 (73.2%) | 0.302 |
| 2 lesions | 5 (13.6%) | 0 (0%) | 5 (19.2%) | |
| 3 lesions | 1 (2.7%) | 0 (0%) | 1 (3.8%) | |
| 5 lesions | 1 (2.7%) | 0 (0%) | 1 (3.8%) | |
| Site of metastases treated with MDT | ||||
| Lymph nodes | 24 (64.9%) | 7 (63.6%) | 17 (65.4%) | 0.582 |
| Bones | 11 (29.7%) | 4 (36.4%) | 7 (27.0%) | |
| Both | 2 (5.4%) | 0 (0%) | 2 (7.6%) | |
| MDT total dose | 34.99 ± 3.54 | 34.09 ± 2.02 | 35.37 ± 3.99 | 0.324 |
| MDT biologically effective dose | 112.08 ± 14.21 | 111 ± 15.51 | 112.56 ± 13.91 | 0.766 |
| Progression | 15 (40.5%) | 9 (81.8%) | 6 (23.1%) | 0.001 |
Continuous and dichotomous variables were compared with the t-test and the chi-square test, respectively. Significant p-values are bolded. Abbreviations: ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; ISUP, International Society of Urological Pathology; MDT, metastasis-directed therapy; PSA, prostate-specific antigen.